文献速递角膜与眼表疾病小儿眼科与斜弱视

儿童过度使用电子屏幕与严重睑板腺萎缩相关

New Indicator of Children's Excessive Electronic Screen Use and Factors in Meibomian Gland Atrophy.
PubMed 文献 · Am J Ophthalmol · 2021-04-17

这项回顾性横断面研究纳入41名6-17岁儿童,发现严重睑板腺萎缩(MGA)病例中86%每日电子屏幕使用≥4小时,而对照组无一超过2小时;屏幕使用增加与睑板腺萎缩分级加重正相关(OR 2.74,95%CI 1.39-5.41)。严重MGA病例均伴有干眼症状/体征,部分自身免疫生物标志物阳性但与MGA无显著关联。

要点

  • 严重睑板腺萎缩患儿中86%每日屏幕使用≥4小时,50%≥8小时,对照组均≤2小时。
  • 屏幕使用时间增加与睑板腺萎缩分级加重正相关(OR 2.74,95%CI 1.39-5.41)。
  • 严重MGA患儿均出现干眼症状/体征,包括角膜新生血管(29%)和视力下降(41%)。

核心结论

  • 儿童过度使用电子屏幕与严重睑板腺萎缩相关。
  • 严重睑板腺萎缩患儿均伴有干眼症状/体征,但自身免疫生物标志物阳性与严重MGA无显著关联。

研究设计与样本

  • 共评估172名儿童,最终41名符合纳入标准(平均年龄11岁,49%女性),其中17例严重MGA,24例对照。
  • 通过问卷评估干眼症状、每日电子屏幕使用小时数、饮食和户外时间,睑板腺成像评估萎缩分级(≥2级为严重)。
  • 对16例严重MGA病例检测自身免疫疾病生物标志物。

主要发现

  • 严重MGA病例中86%报告每日电子屏幕使用≥4小时,50%报告≥8小时;对照组无一超过2小时。
  • 屏幕使用增加与睑板腺萎缩分级加重正相关(OR 2.74,95%CI 1.39-5.41)。
  • 所有严重MGA病例均有干眼症状/体征:角膜新生血管29%,最佳矫正视力下降41%,中央角膜新生血管14%。
  • 对照组无显著干眼症状/体征,且睑板腺分级优于病例组(P < .01)。
  • 16例严重MGA病例中62.5%自身免疫生物标志物阳性(18.8%类风湿因子,6.25% SS-A/SS-B,31.3%早期干燥综合征标志物,6.25% ANA阳性/RF阴性),但与对照组比较无显著关联(右眼P = .34,左眼P = .71)。

关键数值与推荐

  • 严重睑板腺萎缩定义为睑板腺成像≥2级萎缩(基于4点ImageJ量表:0正常-3严重,至少一个眼睑)。
  • 对照组为年龄匹配、萎缩不显著(<1级萎缩)的儿童。

临床怎么用

  • 对儿童干眼症状或视力下降者,应询问每日电子屏幕使用时间并考虑睑板腺成像评估。
  • 每日屏幕使用≥4小时可能提示严重睑板腺萎缩风险增加,需加强干预和随访。
  • 严重睑板腺萎缩患儿可考虑自身免疫生物标志物筛查,但阳性结果与MGA的关联尚不明确。

局限性

  • 回顾性横断面设计无法确定因果关系。
  • 样本量较小(41例),且来自单一临床实践。
  • 自身免疫生物标志物仅在16例严重MGA病例中检测,未在对照组中系统评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the association of children's daily electronic screen use with severe meibomian gland atrophy (MGA). DESIGN: Retrospective cross-sectional study. METHODS: Children (aged 6-17years) presenting at clinical practice December 2016 - October 2017 were evaluated for ≥grade 2 MGA vs age-matched controls with insignificant atrophy (<grade 1 atrophy). Questionnaires assessed dry eye symptoms, daily electronic screen use hours, diet, and outdoor time. Meibography imaging assessed for severe meibomian gland atrophy (≥grade 2 atrophy; ≥1 eyelid on validated, 4-point, ImageJ scale: 0 [normal] - 3 [severe]). Autoimmune disease biomarker positivity was assessed in 16 severe meibomian gland atrophy cases after being found relevant in firstcase. RESULTS: A total of 172 children were evaluated. Patients with known meibomian gland atrophy causes or poor-quality meibographies were excluded. Forty-one met inclusion criteria (mean age, 11 years; 49% female): 17 cases had severe meibomian gland atrophy; 24 controls had insignificant gland atrophy. All severe meibomian gland atrophy cases had ocular symptoms/signs of dry eye disease including corneal neovascularization (29%), best-corrected visual acuity loss (41%), and central corneal neovascularization (14%). No controls had significant dry eye symptoms/signs. Controls had lower/"better" meibogrades vs cases (P < .01). In severe meibomian gland atrophy cases, 86% reported ≥4 hours of daily electronic screen use; 50% reported ≥8 hours. No controls exceeded 2 hours. Increased electronic screen use was positively associated with increased/"worse" meibogrades (odds ratio: 2.74; 95% confidence interval, 1.39-5.41). In 16 severe meibomian gland atrophy cases, 62.5% tested positive for autoimmune biomarker(s), though none had systemic symptoms: 18.8% rheumatoid factor; 6.25% SS-A/SS-B; 31.3% early Sjögren syndrome biomarkers; 6.25% ANA-positive/RF-negative. Autoimmune disease biomarker positivity was not significantly associated with severe meibomian gland atrophy vs controls (P = .34, right-eye; P = .71, left-eye). CONCLUSIONS: Children's excessive electronic screen use is associated with severe meibomian gland atrophy. Further research is needed to establish formal electronic screen use limits based on meibography grade and evaluate correlation of autoimmune disease biomarker positivity in children with severe meibomian gland-atrophy.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cremers SL, Khan ARG, Ahn J, et al. New Indicator of Children's Excessive Electronic Screen Use and Factors in Meibomian Gland Atrophy. Am J Ophthalmol. 2021. PMID: 33857506. doi:10.1016/j.ajo.2021.03.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。